Shopping Cart

Your shopping cart is currently empty

5,7-Dichlorokynurenic acid

Name: 5,7-Dichlorokynurenic acid
Brand: TargetMol
SKU: T22517
Price: 39 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T22517Cas No. 131123-76-7

Alias 5,7-dichlorokynurenic acid sodium, 5,7-DCKA

5,7-Dichlorokynurenic acid (5,7-dichlorokynurenic acid sodium) is an NMDA receptor antagonist.

5,7-Dichlorokynurenic acid

Copy Product Info

😃Good

Purity: 99.71%

Catalog No. T22517Alias 5,7-dichlorokynurenic acid sodium, 5,7-DCKACas No. 131123-76-7

5,7-Dichlorokynurenic acid (5,7-dichlorokynurenic acid sodium) is an NMDA receptor antagonist.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$39	In Stock	In Stock
10 mg	$68	In Stock	In Stock
25 mg	$148	In Stock	In Stock
50 mg	$259	In Stock	In Stock
100 mg	$387	In Stock	In Stock
500 mg	$897	Inquiry	Inquiry

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.71%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

5,7-Dichlorokynurenic acid AI Summary

5,7-Dichlorokynurenic acid exhibits diverse bioactivities with a primary focus on NMDA receptor modulation and anticonvulsant properties. It shows high affinity for the glycine site of the NMDA receptor, displacing [3H]glycine with an IC50 value of 64.0 nM and a Ki value of 40.0 nM. Additionally, it displays moderate inhibition of NMDA-induced depolarizations in rat cortical slices with a Kb value of 3000.0 nM. The compound demonstrates a strong ability to suppress spontaneous epileptiform discharges in cortical wedge models with an IC50 of 5000.0 nM. Furthermore, it inhibits depolarizations induced by AMPA and NMDA in mouse cortical wedge preparations showing IC50 values of 52000.0 nM and 4700.0 nM, respectively. 5,7-Dichlorokynurenic acid also displays limited affinity for AMPA and kainate receptors, with IC50 values exceeding 10000.0 nM for these receptors, except for a minor inhibition of 5.0% at 32 uM for AMPA and 8.0% for kainate receptors. In in vivo models, it exhibits anticonvulsant activity with an ED50 of 7.5 nM when administered intracerebroventricularly but shows less potency intraperitoneally. Moreover, the compound demonstrates additional inhibitory effects, such as displacement of [3H](+)-MK-801 from NMDA receptor sites (IC50 of 860.0 nM) and specific binding activities measured against glutamate receptor subtypes and cyclic GMP accumulation in neonatal rat cerebral slices. Lastly, 5,7-Dichlorokynurenic acid displays bioactivity involved with SARS-CoV-2, inhibiting viral-induced cytotoxicity in Caco-2 and VERO-6 cells at 10 uM concentrations and showing an 18.2% inhibition of SARS-CoV-2 3CL-Pro protease at a concentration of 20 µM..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	5,7-Dichlorokynurenic acid (5,7-dichlorokynurenic acid sodium) is an NMDA receptor antagonist.
Synonyms	5,7-dichlorokynurenic acid sodium, 5,7-DCKA

Chemical Properties

Molecular Weight	258.06
Formula	C₁₀H₅Cl₂NO₃
Cas No.	131123-76-7
Smiles	OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1
Relative Density.	1.701 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 55 mg/mL (213.13 mM), Sonication is recommended.

1eq. NaOH: 100 mM, Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (9.69 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

1eq. NaOH/DMSO

	1mg	5mg	10mg	50mg
1 mM	3.8751 mL	19.3753 mL	38.7507 mL	193.7534 mL
5 mM	0.7750 mL	3.8751 mL	7.7501 mL	38.7507 mL
10 mM	0.3875 mL	1.9375 mL	3.8751 mL	19.3753 mL
20 mM	0.1938 mL	0.9688 mL	1.9375 mL	9.6877 mL
50 mM	0.0775 mL	0.3875 mL	0.7750 mL	3.8751 mL
100 mM	0.0388 mL	0.1938 mL	0.3875 mL	1.9375 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc